Help employers find you! Check out all the
COLORADO SPRINGS, Colo., Aug. 5, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is encouraged by recent polling data by Quinnipiac University showing widespread support among voters in Florida for November's upcoming constitutional referendum on medical cannabis. The most recent study shows 88 percent of Florida voters are in favor of cannabis for medical uses.
"It is encouraging that polling data are so favorable in Florida for the state's upcoming medical cannabis referendum. As a bipartisan state with significant political power and large population, Florida's voters may provide another tipping point in the medical cannabis movement with ramifications for patients not only in Florida but also throughout the entire country," said Chad S. Johnson, Director, COO and General Counsel, Cannabis Science, Inc.
Cannabis Science and its partners are already looking at medical cannabis opportunities in Florida in anticipation of legalization in the state, from research to treatment of critical ailments.
Click here for the results of the Quinnipiac University Poll - Florida and Medical Cannabis.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
Robert Kane, CFO & Director
Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
SOURCE Cannabis Science, Inc.